Physician profile
Ashima Aneja
NPI 1851711022
$2,589.88
in general payments reported to CMS, 2019-2025
25 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,126 · 2020: $219 · 2022: $13.32 · 2023: $266 · 2024: $440 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $308.22 | 2019-2024 | Rexulti |
| Abbvie INC. | $248.43 | 2022-2025 | Vraylar, Botox |
| Bausch Health US, LLC | $190.59 | 2019-2024 | Aplenzin, Wellbutrin |
| Validus Pharmaceuticals LLC | $186.16 | 2023-2024 | Equetro |
| Takeda Pharmaceuticals U.S.A., INC. | $173.28 | 2019-2025 | Trintellix |
| Allergan, INC. | $159.83 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $118.52 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $112.27 | 2019-2023 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $112.03 | 2019-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $108.42 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $99.78 | 2019 | |
| Neurocrine Biosciences, INC. | $91.02 | 2019-2025 | Ingrezza |
| Shire North American Group INC | $86.98 | 2019 | |
| Neos Therapeutics, Lp | $80.78 | 2019-2025 | Adzenys Xr-Odt |
| Lundbeck LLC | $80.38 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.01 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $61.33 | 2024-2025 | Spravato |
| Axsome Therapeutics, INC. | $59.39 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $56.20 | 2024-2025 | Qelbree |
| Tris Pharma INC | $50.22 | 2019-2024 | Dyanavel Xr |
| Arbor Pharmaceuticals, INC. | $42.64 | 2019-2020 | |
| Adlon Therapeutics L.P. | $36.42 | 2019 | |
| Jazz Pharmaceuticals INC. | $29.66 | 2019-2020 | |
| Harmony Biosciences LLC | $15.61 | 2024 | |
| Vertical Pharmaceuticals, LLC | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashima Aneja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.